United States
Securities and Exchange Commission
Washington, D.C. 20549
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(A) OF
THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. )
| Filed by Registrant | ☒ |
| Filed by a Party other than the Registrant | ☐ |
Check the appropriate box:
| ☐ | Preliminary Proxy Statement |
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐ | Definitive Proxy Statement |
| ☒ | Definitive Additional Materials |
| ☐ | Soliciting Material Under Rule 14a-12 |
LANTERN PHARMA INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
| ☒ | No fee required. |
| ☐ | Fee paid previously with preliminary materials |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |
Lantern Pharma Reports First Quarter 2022 Financial Results and Operational Highlights
| ● | RADR®, Lantern’s proprietary A.I. and machine learning platform, has now surpassed 20 billion data points, enhancing its precision, insights, and capabilities for oncology drug discovery |
| ● | Launch and enrollment of the HARMONIC™ clinical trial expected in Summer of 2022; the Phase 2 trial is for LP-300 in never-smokers with lung cancer |
| ● | IND application for LP-184 targeted for submission with the FDA in Q3 2022; enabling a first in-human clinical trial for genomically defined solid tumors |
| ● | Announced brain metastases as a new indication being pursued for LP-184 at the American Association of Cancer Research annual meeting |
| ● | Advanced preclinical studies are underway in Australia, through Australian subsidiary, Lantern Pharma Australia Pty Ltd., to take advantage of Australia’s R&D Tax Incentive program |
| ● | $65.2 million of cash, cash equivalents and marketable securities as of March 31, 2022 |
| ● | $5.3 million in cash was utilized during the three months ended March 31, 2022, of which $2.5 million was for the share repurchase program, with the remainder primarily attributable to core operations |
| ● | Conference call scheduled for 4:30 p.m. EST / 1:30 p.m. PST today |
DALLAS, May 3, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced financial results and operational highlights for the first quarter ended March 31, 2022.
“Lantern is at a very exciting inflection point as we continue to make significant and meaningful progress in translating key insights generated by our A.I. platform into preclinical and clinical programs,” stated Panna Sharma, President and CEO of Lantern Pharma. “Our proprietary RADR® A.I. platform recently surpassed 20 billion data points and is on a solid trajectory to surpass our year-end goal of 25 billion data points. This accelerates our ability to generate new insights to further power our development decisions for our drug candidates, as well as drug candidates from our biopharma collaborators.”
“In mid-April, an amendment to the IND application for the planned Phase 2 trial for LP-300, the HARMONIC™ clinical trial, was submitted to the FDA. The Harmonic™ trial is focused on never-smokers with non-small cell lung cancer (NSCLC) and is expected to begin enrolling patients in the second half of this year. Additionally, we remain on track to launch up to two Phase 1 trials for LP-184 in cancers with significant clinical need. We also anticipate reporting data from multiple preclinical programs this year, including programs focused on pediatric cancers and those that exploit the synthetic lethality potential of our compounds.” continued Sharma.
Operational Highlights:
RADR® Platform Growth and Development
| ● | Surpassed 20 billion data points for RADR® A.I. platform and we expect to reach our goal of over 25 billion data points by year end. | |
| ● | RADR® utilizes over 150 different algorithms that have yielded insights for our drug programs. These algorithms are focused on critical questions in oncology drug discovery and development. | |
| ● | Filed a patent application covering claims for the development of ensemble and deep learning methods and algorithms, including automated algorithm development within RADR®. | |
| ● | Future RADR® growth will focus on additional functionality and modules that aid in the discovery and development of compounds that can leverage synthetic lethality, and in the prediction of potential combination regimens across multiple drug classes, including those that have not previously been utilized in cancer. |
Lantern’s Portfolio of Targeted Therapies
Lantern Pharma is currently developing four drug candidates and an Antibody-Drug Conjugate (ADC) program across nine disclosed tumor targets, and several undisclosed targets. Lantern’s portfolio currently includes:
| ● | LP-300 - is preparing to enter a Phase 2 clinical trial, the HARMONIC™ clinical trial, in the Summer of 2022. The HARMONIC™ trial will be a 90 patient, two-arm, randomized, open label clinical trial focused on never-smoker patients with relapsed primary adenocarcinoma of the lung, a type of NSCLC. An amendment to the IND, including a finalized clinical study protocol, was submitted to the FDA in mid-April and the first patients are anticipated to be enrolled in the Summer of 2022. The HARMONIC™ trial is anticipated to include 15-20 sites in the US, of which multiple are currently being contracted for enrollment. |
| ● | LP-100 - is in a Phase 2 trial in Denmark for patients with metastatic castration resistant prostate cancer (mCRPC) that meet a certain genomic signature that correlates to enhanced sensitivity to LP-100. In the initial cohort of patients, nine patients experienced a median overall survival of 12.5 months. We are evaluating possibilities for further enrollment in the current Phase 2 trial as well as other potential clinical development opportunities that we believe can further de-risk the program while increasing the potential for patient benefit that exceeds the current standards of care. |
Based on existing data demonstrating synergy between LP-100 and PARP inhibitors, we are currently investigating the potential of combination therapy for these two agents.
| ● | LP-184 - is in preparation for potentially multiple Phase 1 clinical trial launches for genomically defined pancreatic and bladder cancers as well as CNS cancers including glioblastoma multiforme (GBM), atypical teratoid rhabdoid tumors (ATRT), and brain metastases (brain mets). |
The IND enabling studies for LP-184 are in progress and are anticipated to be completed by Q3 2022. Based on current timeline projections, the Company is targeting to file the LP-184 IND submission with the FDA in Q3 and should be in a position to initiate in-human Phase 1 clinical testing before the end of 2022.
2
Lantern announced data supporting the efficacy of LP-184 in brain mets in a poster at the American Association for Cancer Research (AACR) 2022 annual meeting. The poster highlighted the in vitro anti-tumor activity of LP-184 in brain mets cell models from lung, skin, and breast cancers. In the US, brain mets occur in around 10-30% of all cancer cases and are diagnosed in well over 100,000 patients each year.
There is an urgent and unmet clinical need for new therapies for brain mets due to a current lack of novel agents that can cross the blood brain barrier (BBB). LP-184’s favorable BBB permeability, paired with its observed preclinical efficacy in certain CNS cancers, underscore its potential to become a vital treatment option for patients relapsed from current standard of care treatment or for use in combination with other agents.
| ● | LP-284 - is in preclinical development and has demonstrated potency at low nanomolar levels in hematological cancer cell lines, including lymphoma, multiple myeloma, and leukemia. LP-284’s indications in hematological cancers are distinct from the indications targeted by LP-184 and were generated with the assistance of RADR® insights. |
| ● | Antibody Drug Conjugate (ADC) Program - we have selected and ranked multiple targeting antibodies of interest with potential to be linked to selected cytotoxic payloads. We are in late-stage candidate selection of various cytotoxic compounds and targeted classes of agents to be used as ADC payloads. |
Establishment of Australian Subsidiary
| ● | In September 2021, Lantern created an Australian subsidiary, Lantern Pharma Australia Pty Ltd. The subsidiary was created to enable Lantern to take advantage of Australia’s R&D Tax Incentive program, which provides tax offsets for eligible R&D expenditures. | |
| ● | This program will provide the opportunity for Lantern to conduct upcoming preclinical and clinical trials with increased financial flexibility and capital efficiency. Lantern has already initiated preclinical and IND enabling studies under the subsidiary in Australia. | |
| ● | Lantern may conduct first in-human phase 1 clinical trials in Australia due to its historical capability for cost-effectiveness, accelerated timelines, and timely regulatory approval. We believe that this aligns with the Company’s focus to develop oncology therapies with reduced time and cost. |
Scientific Collaborations Updates
| ● | In early 2022, Lantern entered a collaboration with The Greehey Children’s Cancer Research Institute (GCCRI) at University of Texas Health Science Center-San Antonio to expand Lantern’s drug portfolio research into several additional pediatric cancers with unmet clinical needs. | |
| ● | The studies from this collaboration have been initiated beginning with LP-184 treatment of nine in vitro models of pediatric cancers. The preliminary results have been promising and will be completed in Q2 2022. | |
| ● | Lantern is evaluating additional collaborations with leading academic cancer institutions and researchers for LP-284. |
3
First Quarter 2022 Financial Overview
| ● | Balance Sheet: Cash, cash equivalents, and marketable securities were $65.2 million as of March 31, 2022, compared to $70.7 million as of December 31, 2021. The quarterly cash burn continues to reflect our capital-efficient, collaborator-centered business model. $5.3 million in cash was utilized during the three months ended March 31, 2022, of which $2.5 million was for the share repurchase program, with the remainder primarily attributable to core operations. | |
| ● | R&D Expenses: Research and development expenses were $2.7 million for the quarter ended March 31, 2022 compared to $1.3 million for the quarter ended March 31, 2021. The increase in R&D expense was primarily attributable to increases in manufacturing related expenses for product candidates, research studies, and an escrow payment released to Allarity under the Allarity Asset Purchase Agreement, which payment was a nonrecurring expense. | |
| ● | G&A Expenses: General and administrative expenses were $1.4 million for the quarter ended March 31, 2022 compared to $1.2 million for the quarter ended March 31, 2021, respectively. | |
| ● | Net Loss: Net loss was $4.1 million (or $0.38 per share) for the quarter ended March 31, 2022, compared to a net loss of $2.5 million (or $0.24 per share) for the quarter ended March 31, 2021. |
Additional Financial Highlights
| ● | In March 2022, Lantern’s Board of Directors authorized an extension of the existing share repurchase program to acquire up to $7 million of the Company’s common stock. Under the share repurchase program, through March 31, 2022 the Company has purchased a total of 475,157 shares of its common stock at a total cost of approximately $3.4 million, including fees. The Company is authorized to additionally purchase up to a total of $3.6 million of the Company’s common stock through July 31, 2022, pursuant to the repurchase program. |
Nomination of New Board Member for Election and Annual Meeting of Stockholders
| ● | Lantern recently announced that Dr. Maria Maccecchini, Ph.D. was nominated for election to our Board of Directors. She is the current CEO, President, and a Director of Annovis Bio Inc., a biopharma company focused on developing therapies for neurodegenerative diseases. If elected, Dr. Maccecchini will bring decades of experience in progressing drug candidates through late-stage clinical trials. Dr. Maccecchini will be presented alongside a slate of five existing Directors at Lantern’s upcoming Annual Meeting of Stockholders to be held on June 8, 2022. Additionally, Leslie W. Kreis, Jr., a member of Lantern Pharma’s Board of Directors since 2019, has advised Lantern’s Board of his determination not to stand for reelection as a Director at Lantern’s Annual Meeting. |
| ● | The Annual Meeting of Stockholders will be held on June 8, 2022 at 11:00 am EST/ 8:00 am PST, which will be held via webcast. Register for the Annual Meeting here. |
2022 Outlook:
“During the year we expect to bring multiple assets into focused clinical trials where there is demonstrated clinical need, while remaining focused on capital efficiency. Additionally, our A.I. platform, RADR®, will continue to grow significantly across all measures - data, analytical rigor, generation of new publishable insights, and new functionality. As data and A.I. continue to drive changes in the cost, speed and efficiency of drug discovery and development, our team at Lantern will remain at the forefront of transforming oncology therapeutic development.”
Earnings Call and Webinar Details
Lantern will host its first quarter fiscal year 2022 earnings call and webinar today, Tuesday, May 3 at 4:30 p.m. ET.
| ● | https://us06web.zoom.us/webinar/register/3516500329459/WN_fOeTQP8mRru_FxXFWsR69w | |
| ● | Related presentation materials will be accessible at: https://ir.lanternpharma.com |
4
Replay Details
| ● | A replay of the Q1 2022 earnings call and webinar will be available at https://ir.lanternpharma.com. |
Lantern’s Investor Relations Contact:
Nicole Leber
Investor Relations Associate
ir@lanternpharma.com
About Lantern Pharma
Lantern Pharma (NASDAQ: LTRN) is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR® A.I. and machine learning platform to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically targeted therapeutics. Lantern is currently developing four drug candidates and an ADC program across nine disclosed tumor targets, including two phase 2 programs. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, Lantern’s approach represents the potential to deliver best-in-class outcomes.
Please find more information at:
Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/
Twitter: @lanternpharma
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “objective,” “aim,” “upcoming,” “should,” “will,” “would,” or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that our research and the research of our collaborators may not be successful, (iii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iv) the risk that no drug product based on our proprietary RADR® A.I. platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (v) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 10, 2022. You may access our Annual Report on Form 10-K for the year ended December 31, 2021 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC’s website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.
5
First Quarter 2022 Operating & Financial Results Conference Call / Webinar May 3 rd , 2022 4:30 PM Eastern Time NASDAQ :LTRN
First Quarter 2022 Earnings 7KLVSUHVHQWDWLRQFRQWDLQVIRUZDUG ORRNLQJVWDWHPHQWVZLWKLQWKHPHDQLQJRI6HFWLRQ $RIWKH6HFXULWLHV$FWRI DVDPHQGHGDQG 6HFWLRQ (RIWKH6HFXULWLHV([FKDQJH$FWRI DVDPHQGHG7KHVHIRUZDUG ORRNLQJVWDWHPHQWVLQFOXGHDPRQJRWKHUWKLQJVVWDWHPHQWV UHODWLQJWR IXWXUHHYHQWVRURXUIXWXUHILQDQFLDOSHUIRUPDQFH WKHSRWHQWLDODGYDQWDJHVRIRXU5$'5 p SODWIRUPLQLGHQWLI\LQJGUXJFDQGLGDWHV DQGSDWLHQWSRSXODWLRQVWKDWDUHOLNHO\WRUHVSRQGWRDGUXJFDQGLGDWH RXUVWUDWHJLFSODQVWRDGYDQFHWKHGHYHORSPHQWRIRXU GU XJ FDQGLGDWHVDQGDQWLERG\GUXJFRQMXJDWH $'&GHYHORSPHQWSURJUDP HVWLPDWHVUHJDUGLQJWKHGHYHORSPHQWWLPLQJIRURXUGUXJFDQ GLG DWHV DQG$'&GHYHORSPHQWSURJUDP RXUUHVHDUFKDQGGHYHORSPHQWHIIRUWVRIRXULQWHUQDOGUXJGLVFRYHU\SURJUDPVDQGWKHXWLOL]DWLRQ RI RXU 5$'5 p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Ȋ REMHFWLYH ȋ DLP ȋȊ XSFRPLQJ ȋ VKRXOGZLOOZRXOGRUWKHQHJDWLYHRIWKHVHZRUGVRU RWKHUVLPLODUH[SUHVVLRQVVKRXOGEHFRQVLGHUHGIRUZDUG ORRNLQJVWDWHPHQWV7KHUHDUHDQXPEHURILPSRUWDQWIDFWRUVWKDWFRXOGF DXVHRXU DFWXDOUHVXOWVWRGLIIHUPDWHULDOO\IURPWKRVHLQGLFDWHGE\WKHIRUZDUG ORRNLQJVWDWHPHQWVVXFKDV L WKHLPSDFWRIWKH&29Ζ' SDQGHPLF LLWKHULVNWKDWRXUUHVHDUFKDQGWKHUHVHDUFKRIRXUFROODERUDWRUVPD\QRWEHVXFFHVVIXO LLLWKHULVNWKDWZHPD\QRWE HD EOHWRVXFFHVVIXOO\ LQLWLDWHFRQGXFWRUFRQFOXGHFOLQLFDOWHVWLQJIRURUREWDLQPDUNHWLQJDSSURYDOIRURXUSURGXFWFDQGLGDWHV LYWKHULVNWK DW QRGUXJSURGXFW EDVHGRQRXUSURSULHWDU\5$'5 p $Ζ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orward - Looking Statements 1
Contents 01 Introduction 02 Q1 2022 Highlights 03 Scientific Progress 04 Financial Highlights 05 Q&A Speakers Panna Sharma Chief Financial Officer ΖQYHVWRU5HODWLRQV Chief Executive Officer, President and Director David Margrave Nicole Leber Chief Scientific Officer Dr. Kishor Bhatia Host
First Quarter 2022 Earnings Lantern Pharma Leveraging A.I. to reduce oncology drug development costs and improve the likelihood of success Abundance of data Proprietary A.I. platform RADR ® Accelerated timeline and reduced cost
First Quarter 2022 Earnings Australia Operation • Actively conducting multiple studies in Australia under Lantern Australian subsidiary • Takes advantage of R&D tax incentive program 5$'5 p ([SDQVLRQ ‡ 5$'5 p KDVVXUSDVVHG ELOOLRQGDWDSRLQWV ‡ 3XUVXLQJDGGLWLRQDOELRSKDUPDFROODERUDWLRQV Share Repurchases • Announced extension of existing share repurchasing program Pediatric Cancer • Initiated work with Greehey Children’s Cancer Institute at UT Health San Antonio • Early preclinical efficacy seen in initial studies +DUPRQLF Ƞ 7ULDO • Submitted IND amendment including a finalized clinical study protocol to the FDA in mid - April for Phase 2 trial • 1st patient anticipated in Summer 2022 LP - 184 • IND enabling studies progressing • IND submission targeted in Q3 2022 Brain Metastases • Presented poster and findings at AACR • Pursuing new indication for LP - 184 in a market with significant unmet clinical need Synthetic Lethality • Evidence of a synthetic lethal relationship between LP - 184 and NERD and HRD tumors 4 First Quarter 2022 Highlights
First Quarter 2022 Earnings +DUPRQLF Ƞ &OLQLFDO7ULDO Ȃ 3KDVH 7ULDOIRU/3 5 ‡ +DUPRQLF Ƞ FOLQLFDOWULDOLVD3KDVH PXOWL FHQWHUVWXG\WR HYDOXDWH/DQWHUQ ȇ VLQYHVWLJDWLRQDOGUXJ/3 ‡ SDWLHQWWZR DUPRSHQODEHO UDQGRPL]HGWULDO ‡ UDQGRPL]DWLRQLQD DOORFDWLRQUDWLRWRRQHRIWZRDUPV ‡ 7ULDOLVIRFXVHGRQ QHYHUVPRNHU SDWLHQWVZLWKUHODSVHG SULPDU\DGHQRFDUFLQRPDRIWKHOXQJDW\SHRI16&/& 1RQ 6PDOO&HOO/XQJ&DQFHU ΖQDVXEVHWRI1HYHU6PRNHUSDWLHQWVIURPDODUJHU16&/&WULDO SDWLHQWVZKRUHFHLYHG/3 ZLWKFKHPRWKHUDS\VKRZHG LQFUHDVHG RYHUDOODQG \HDUSDWLHQWVXUYLYDOE\ DQG UHVSHFWLYHO\ Total expected patients 90 Patients Total expected sites 15 - 20 Sites (VWLPDWHGILUVWSDWLHQWHQUROOPHQW Summer 2022 <HDU6XUYLYDO 2YHUDOO6XUYLYDO 125% median survival increase median survival increase
First Quarter 2022 Earnings /3 Ζ1'HQDEOLQJVWXGLHV 6 Completed Ongoing Expected 6WXG\7\SH Method Results Dog non - GLP tox study NOAEL 0.3mg/kg for repeat weekly dosing (days 1, 8 and 15) At NOAEL in dogs LP - 184 PK parameters measured on dosing days 1 and 15 showed ○ t1/2 = 40 - 50 min ○ Cmax = 800 nM ○ Tmax = 5 min ○ At 0.3mg/kg some hematotoxicity observed in form of decreased counts of blood lymphocytes Analytical Method Development Completed LC - MS method development for rat/ dog plasma, and matrix/ storage/ pH/ freeze - thaw stability; precision & accuracy Standard curve: 1 - 200 ng/mL; QC levels: 1, 3, 75, 180, 200 ng/mL Study Type Method Expected completion Analytical Method Validation 30 - day stability protocols June 2022 Dog GLP 3 weekly doses (0.2, 0.4 and 0.6mg/kg) Early June 2022 6(1'UHSRUWIRUPDW WR)'$ CMC data for FDA IND filling 3KDVH /3 WULDO Targeted for Q3 Targeted for Q4
First Quarter 2022 Earnings In vitro efficacy of our drug candidate LP - 184 in brain metastases ( mets .) , • LP - 184 has activity in the primary and secondary cancers AND crosses the BBB. • Efficacy of LP - 184 may extend beyond primary brain cancers to other solid tumors that have metastasized to the brain as evidenced by in vitro efficacy in brain mets . cell lines. • LP - 184 demonstrated anti - tumor activity in brain metastases cell models from lung, skin, and breast cancers. • Data supports continued development of LP - 184 in these CNS cancer indications LP - 184 is 6X more potent than early generation EGFR TKIs in brain metastasis models from primary lung cancer 8QPHW&OLQLFDO1HHG LQ%UDLQ0HWDVWDVHV • Brain metastases in the U.S. occur in 10 - 30% of all cancer cases and are diagnosed in over 100,000 patients each year. • There is an urgent and unmet clinical need for novel therapies for brain mets due to a current lack of novel agents that can cross the blood brain barrier (BBB). $ 9 Billion US Market Potential Estimated
First Quarter 2022 Earnings /DQWHUQHVWDEOLVKHGDQ$XVWUDOLDQVXEVLGLDU\ 8 Subsidiary will allow: o Lantern to take advantage of Australia’s R&D Tax Incentive program, which provides tax offsets for eligible R&D expenditures o Lantern to conduct preclinical and IND enabling studies, many of which are already underway o Increases financial flexibility and improves capital efficiency for ongoing R&D activity /DQWHUQ3KDUPD$XVWUDOLD3W\/WGD/DQWHUQVXEVLGLDU\ZDVHVWDEOLVKHGLQ$XVWUDOLDLQ6HSWHPEHU Established Australia subsidiary to take advantage of Australia’s Research & Development Tax Incentive
First Quarter 2022 Earnings RADR ® Surpassed 20 Billion Datapoints 9 2019 2020 Apr. 2021 Dec. 2021 2022* Ēĕ 8 100M 275M 450M 1.1 B ĔĽĖſ 10.4 B 2XUJRDOLVWRH[SDQG 5$'5WR ELOOLRQGDWDSRLQWV GXULQJ 1. Focus on automation of data acquisition 2. Improve data user interface to other analytical tools and containers 3. Improve tagging of metadata 4. Enter into additional value - based biopharma collaborations Future Goals For A.I. Platform
First Quarter 2022 Earnings LP - 300 Mechanism of action 3URWHLQ'HJUDGDWLRQ Panel A : LP - 300 adduct at Cys 1235 Panel B : LP - 300 adduct at Cys 1156 Panel C : Molecular surface of ALK with the LP - 300 - derived adduct at Cys 1156 ( yellow highlight ) Panel D : Binding site of the LP - 300 - derived adduct at Cys 1235 ( yellow highlight ) LP - 300 can degrade NSCLC proteins such as EGFR, ALK and ROS via cysteine modification (OHFWURQGHQVLW\PDSVVKRZLQJ/3 GHULYHG DGGXFWVRQ$/. • LP - 300 in previous clinical trials has been well tolerated in around 1,000 people . • In a subset of Never Smoker patients from a larger NSCLC trial, patients who received LP - 300 with chemotherapy showed increased overall and 2 - year patient survival by 91% and 125%, respectively. A B C ' LP - 300 Target Modulation /3 PRGXODWHVWDUJHWVZLWKLQNH\VLJQDOLQJSDWKZD\VLQ16&/& • Receptor Tyrosine Kinases involved in proliferation/ survival signaling pathways ( EGFR, ALK, ROS 1 ) • Enzymes critical for DNA synthesis and repair ( ERCC 1 , RNR 1 , RNR 2 ) • Enzymes and proteins important in regulating cellular redox status ( TRX, PRX, GRX, PDI ) LP - 300 modulates : LP - 300 molecule 10
First Quarter 2022 Earnings LP - 184 IND enabling studies 11 &RPSOHWHG Ongoing Expected 6WXG\7\SH Method Results Dog non - GLP tox study NOAEL 0.3mg/kg for repeat weekly dosing (days 1, 8 and 15) At NOAEL in dogs LP - 184 PK parameters measured on dosing days 1 and 15 showed ○ t1/2 = 40 - 50 min ○ Cmax = 800 nM ○ Tmax = 5 min ○ At 0.3mg/kg some hematotoxicity observed in form of decreased counts of blood lymphocytes Analytical Method Development Completed LC - MS method development for rat/ dog plasma, and matrix/ storage/ pH/ freeze - thaw stability; precision & accuracy Standard curve: 1 - 200 ng/mL; QC levels: 1, 3, 75, 180, 200 ng/mL Study Type Method Expected completion Analytical Method Validation 30 - day stability protocols June 2022 Dog GLP 3 weekly doses (0.2, 0.4 and 0.6mg/kg) Early June 2022 SEND report format to FDA CMC data for FDA IND filling Phase 1 LP - 184 trial Targeted for Q3 7DUJHWHGIRU4
First Quarter 2022 Earnings In vitro efficacy of our drug candidate LP - 184 in brain metastases ( mets .) , 12 • LP - 184 has activity in the primary and secondary cancers AND crosses the BBB. • Efficacy of LP - 184 may extend beyond primary brain cancers to other solid tumors that have metastasized to the brain as evidenced by in vitro efficacy in brain mets . cell lines. • LP - 184 demonstrated anti - tumor activity in brain metastases cell models from lung, skin, and breast cancers. • Data supports continued development of LP - 184 in these CNS cancer indications LP - 184 is 6X more potent than early generation EGFR TKIs in brain metastasis models from primary lung cancer Unmet Clinical Need in Brain Metastases • Brain metastases in the U.S. occur in 10 - 30% of all cancer cases and are diagnosed in over 100,000 patients each year. • There is an urgent and unmet clinical need for novel therapies for brain mets due to a current lack of novel agents that can cross the blood brain barrier (BBB). %LOOLRQ 860DUNHW3RWHQWLDO Estimated
First Quarter 2022 Earnings LP - 184 shows exquisite sensitivity in NERD as well as HRD cancers 13 LP - 184 in HRD cancers LP - 184 in NERD cancers • NERD tumors are nucleotide excision repair deficient tumors whose phenotype is a result of mutations in genes responsible for excision DNA repair - these include but not limited to - ERCC1 , ERCC3, ERCC4, ERCC5, ERCC6, RAD50, ATR, ATM, MRE, CSB , XPD etc. • Mutant cell lines deficient in the Nucleotide Excision Repair (NER) pathway were more sensitive to LP - 184 than the parent cell line ‡ +5' DUH +RPRORJXV UHFRPELQDWLRQGHFLHQWWXPRUVDQG FDUU\PXWDWLRQVLQJHQHVVXFKDV %5&$ %5&$ 3$/% %5,3 )$1&$ HWF ‡ /3 WUHDWPHQWUHVXOWHGLQFRPSOHWHWXPRUUHJUHVVLRQLQD 3';PRGHORI71%&WKDWLV+5GHFLHQWDQGUHVLVWDQWWR 3$53LQKLELWRUVDQGGR[RUXELFLQF\FORSKRVSKDPLGH
First Quarter 2022 Earnings Financial Update Q1 2022 14 2022 2021 Operating expenses : General and administrative 1,406,160 1,173,258 Research and development 2,660,237 1,279,037 Total operating expenses 4,066,397 2,452,295 Loss from operations (2,452,295) Interest + Other income, net (55,377) - NET LOSS $ (4,121,774) $ (2,452,295) Net loss per common share, basic and diluted $ (0.38) $ (0.24) Weighted Avg. Common Shares Outstanding - Basic and Diluted 10,875,777 10,074,623 3/31/2022 12/31/2021 Cash and Marketable Securities $ 65,216,479 $ 70,725,447 Prepaid Expenses & Other Current Assets $ 2,446,679 $ 1,990,953 Total Assets $ 68,402,517 $ 73,950,477 Total Liabilities $ 3,087,145 $ 2,379,057 Total Stockholders’ Equity $ 65,315,372 $ 71,571,420 Summary Results of Operations Balance Sheet Highlights & Summary Three Months Ended March 31, We believe our solid financial position will fuel continued growth and evolution of our RADR ® A.I. platform, accelerate the development of our portfolio of targeted oncology drug candidates and allow us to introduce additional targeted product and collaboration opportunities in a capital efficient manner. ” “ (unaudited) (unaudited)
First Quarter 2022 Earnings LTRN Share Information 15 March 31, 2022 LANTERN PHARMA INC. (LTRN) Common Shares Outstanding 10,830,947 Warrants 177,998 Options (Employees, Management and Directors) 890,826 Fully Diluted Shares Outstanding 11,899,771 Date Shares Repurchased Average Price Total Paid including Commission FY 2021 121,490 $7.71 $939,666 Three months ended March 31, 2022 353,667 $6.86 $2,482,286 Total 475,157 $7.08 $3,421,952 Up to $7 Million is authorized for repurchase under Lantern’s repurchase program, of which approximately $3.6 Million remains av ailable for future purchases.
First Quarter 2022 Earnings Maria Maccecchini , Ph.D. was nominated for election to Lantern’s Board of Directors 16 Maria L. Maccecchini , Ph.D. Founder, President, Chief Executive Officer, and director of Annovis Bio ( NYSE: ANVS ) New Director Nominee Dr. Maccecchini will be presented alongside a slate of five existing Directors at Lantern's upcoming Annual Meeting to be held on June 8, 2022.
First Quarter 2022 Earnings Upcoming Events 9th Drug Discovery Strategic Summit Speaker: Kishor Bhatia MAY 9 13 Strategic Investment Conference Speaker: Panna Sharma MedVentures Conference 2022 Speaker: Panna Sharma 19 Augmented intelligence in drug discovery Xchange east coast, Speaker: Panna Sharma JUNE 23 Bioinformatics Strategy Meeting East Coast USA 2022 Speaker: Panna Sharma 7 World Orphan Drug Congress USA 2022 Speaker: Panna Sharma LD Micro Invitational Speaker: Panna Sharma JULY 11 18 17
First Quarter 2022 Earnings Key Corporate Objectives and Milestones 18 Ɣ /DXQFKRI 7KH+DUPRQLF Ƞ 7ULDO 3K FOLQLFDOWULDOIRU/3 LQ16&/& Ɣ $GYDQFH/3 FOLQLFDOGHYHORSPHQW Ɣ /DXQFK3K FOLQLFDOWULDOIRU/3 LQ JHQRPLFDOO\ GHILQHG VROLGWXPRUV Ɣ 'HVLJQ3K FOLQLFDOWULDOIRU/3 LQ*%0 Ɣ 3URJUHVV/3 LQ$757WRZDUGV3K FOLQLFDOWULDO Ɣ $GYDQFHSHGLDWULFFDQFHUGUXJGHYHORSPHQWSURJUDP Ɣ $GYDQFH$'&SUHFOLQLFDOVWXGLHVWRVXSSRUWIXWXUH3KDVH ODXQFK Ɣ ([SORUHSRWHQWLDOFRPELQDWLRQVIRU/3 /3 /3 /3 ZLWK RWKHUH[LVWLQJDSSURYHGGUXJV Ɣ 6WUDWHJLFDOO\JURZ5$'5 p $ΖSODWIRUPWR ELOOLRQGDWDSRLQWV Ɣ ([SORUHOLFHQVLQJDQGSDUWQHUVKLSRSSRUWXQLWLHV 2022 Objectives and Milestones
Nasdaq: LTRN IR Contact: IR@lanternpharma.com 1 - 972 - 277 - 1136 www.lanternpharma.com @LanternPharma